IPR Strategy – Industry

🎯 Overview

In regulated industries, the intersection of intellectual property and scientific publication is a minefield. Publish too early and you may forfeit patent rights. Publish too late and competitors gain advantage. Our Industry IPR Strategy service provides comprehensive guidance to protect your R&D investments while ensuring your scientists can publish and advance their careers.

Ideal for: Pharmaceutical companies, biotech firms, medical device manufacturers, and CROs with active R&D programs and scientists who need to publish.

✅ What’s Included

Strategic Assessment

• Patent Landscape Analysis – Comprehensive review of existing patents in your research area
• Freedom-to-Operate Assessment – Analysis of potential infringement risks from planned publications
• Competitive Intelligence Review – Monitoring competitor publication and patent activity
• Publication Pipeline Audit – Review of all manuscripts in preparation with IP implications

Policy Development

• Publication-Patent Coordination Policy – Company-wide guidelines for managing disclosure timing
• Inventor Disclosure Procedures – Streamlined process for capturing patentable innovations
• Pre-Publication Review Workflow – System for IP review before any external disclosure
• Conference Presentation Guidelines – Protocols for protecting IP at scientific meetings

Implementation Support

• Training Sessions – IP awareness training for R&D teams (up to 4 sessions)
• Manuscript Review Service – IP assessment of up to 10 manuscripts during engagement
• Patent Timing Recommendations – Strategic advice on provisional vs. full patent applications
• Quarterly Strategy Reviews – Ongoing assessment of publication-patent coordination

⚙️ How It Works

🛡️ Our Assurances

• Confidentiality – All information protected under NDA; no disclosure to third parties
• Patent Attorney Collaboration – We coordinate directly with your patent counsel (or recommend qualified attorneys)
• Regulatory Awareness – Strategies aligned with FDA, EMA, and other regulatory requirements
• Dedicated Team – Senior consultant with pharma/biotech IP experience assigned to your account
• Actionable Deliverables – All recommendations include implementation guidance and templates
• Post-Engagement Support – 90-day email support for questions after engagement concludes

⚠️ Important Limitations

• Not Legal Advice – We provide strategic guidance, not legal opinions. Patent filing decisions require qualified patent attorney review.
• No Patent Filing Services – We do not file patents; we coordinate with your patent counsel on timing and strategy
• 10 Manuscript Limit – Package includes IP review of up to 10 manuscripts; additional manuscripts at $500/each
• One Business Unit – Engagement covers one R&D division or therapeutic area; multi-division pricing available
• Existing IP Only – We assess existing patent landscape; prior art searches for new inventions quoted separately
• English Language – Analysis covers English-language patents and publications; other languages available with translation costs
• Jurisdiction Limitations – Primary focus on US, EU, and major Asian markets; other jurisdictions available on request

📋 Requirements From You

• R&D Pipeline Documentation – Overview of active research programs and development timelines
• Publication Pipeline – List of manuscripts in preparation, under review, or planned
• Existing IP Portfolio – Summary of current patents and applications
• Patent Counsel Contact – Introduction to your patent attorney(s) for coordination
• Key Personnel Access – Availability of R&D leaders for interviews and training sessions
• Current Policies – Existing publication and IP policies for review
• NDA Execution – Mutual confidentiality agreement before engagement begins

❓ Common Questions

Do you work with our patent attorneys or replace them?
We work alongside your patent counsel, never as a replacement. Our expertise is in publication strategy and academic publishing norms; patent attorneys handle legal filings and opinions. The combination ensures both worlds are properly coordinated.

What’s the risk if we publish without proper IP review?
Publishing before filing a patent application can constitute “prior art” that invalidates patent claims in most jurisdictions. In the US, you have a 12-month grace period; in Europe and Asia, any public disclosure before filing can forfeit patent rights entirely.

Can you help with trade secret protection as an alternative to patents?
Yes. Our policy development includes guidance on when trade secret protection may be preferable to patent filing, and how to structure publications to protect trade secrets while still sharing research findings.

What about academic collaborations with universities?
Academic-industry collaborations require careful IP coordination. We help structure publication agreements, manage joint authorship, and coordinate publication timing across institutional boundaries. See also our IPR Strategy – University package.

Do you offer ongoing retainer services?
Yes. Many industry clients transition to our quarterly retainer model ($3,500/quarter) for ongoing manuscript review and strategic guidance. Ask about retainer options during your engagement.